Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that is highly overexpressed in various cancer cells and antigen-presenting cells. It has emerged as an attractive therapeutic target for cancer immunotherapy, which has prompted high interest in the development of small-molecule in...

Full description

Bibliographic Details
Main Authors:	Dong-Ho Lee, Joo-Youn Lee, Jieun Jeong, Miok Kim, Kyung Won Lee, Eunseo Jang, Sunjoo Ahn, Chang Hoon Lee, Jong Yeon Hwang
Format:	Article
Language:	English
Published:	MDPI AG 2017-11-01
Series:	Molecules
Subjects:	indoleamine 2,3-dioxygenase 1 N’-hydroxyindazolecarboximidamide cancer immunotherapy tryptophan depletion kynurenine production
Online Access:	https://www.mdpi.com/1420-3049/22/11/1936

Similar Items

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells
by: Ilona Sadok, et al.
Published: (2021-01-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
by: A. Marijne Heeren, et al.
Published: (2018-07-01)

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
by: Yvonne Grobben, et al.
Published: (2021-01-01)

IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
by: Yu Yao, et al.
Published: (2021-02-01)

The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression
by: Jun-bao Liu, et al.
Published: (2020-01-01)

Diazotization of kynurenine by acidified nitrite secreted from indoleamine 2,3-dioxygenase-expressing myeloid dendritic cells
by: Hara, Toshiaki, et al.
Published: (2008)

Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study
by: Luukkainen Annika, et al.
Published: (2011-12-01)

The role of eosinophils in the neonatal murine thymus; Expression of Indoleamine 2,3-dioxygenase
by: Cravetchi, Olga Vladimir
Published: (2009)

High expression of IDO1 and TGF-β1 during recurrence and post infection clearance with Chlamydia trachomatis, are independent of host IFN-γ response
by: Noa Ziklo, et al.
Published: (2019-03-01)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
by: Takefumi Komiya, et al.
Published: (2018-10-01)

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
by: Hui Wen, et al.
Published: (2019-06-01)

Kynurenines as a Novel Target for the Treatment of Malignancies
by: Adrian Mor, et al.
Published: (2021-06-01)

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
by: Concetta Elisa Onesti, et al.
Published: (2019-07-01)

The Kynurenine Pathway As a Novel Link between Allergy and the Gut Microbiome
by: Aaron P. Van der Leek, et al.
Published: (2017-11-01)

In vitro Effects of Nigella sativa Seeds Extracts on Stimulated Peripheral Blood Mononuclear Cells
by: Winkler Christiana, et al.
Published: (2008-02-01)

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
by: Dyah L. Dewi, et al.
Published: (2017-02-01)

High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells
by: Hara, Toshiaki, et al.
Published: (2008)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
by: Lisa A. Wetzel, et al.
Published: (2020-08-01)

The emerging roles of IDO2 in cancer and its potential as a therapeutic target
by: Pengcheng Li, et al.
Published: (2021-05-01)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
by: Nattawut Wongpraparut, et al.
Published: (2021-07-01)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
by: Andrea Botticelli, et al.
Published: (2020-07-01)

On the nonredundant roles of TDO2 and IDO1
by: Paolo ePuccetti
Published: (2014-10-01)

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
by: Hongchuan Zhao, et al.
Published: (2019-03-01)

Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
by: Pilvi Maliniemi, et al.
Published: (2017-03-01)

Late-stage systemic immune effectors in Plasmodium berghei ANKA infection: biopterin and oxidative stress
by: Dogruman-Al Funda, et al.
Published: (2015-09-01)

The 14kDa Protein Molecule Isolated from Garlic Suppresses Indoleamine 2, 3-Dioxygenase Metabolites in Mononuclear Cells In vitro
by: Nikoo Shohreh, et al.
Published: (2008-12-01)

AncPhore: A versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo-β-lactamases and indoleamine/tryptophan 2,3-dioxygenases
by: Qingqing Dai, et al.
Published: (2021-07-01)

Local Inhibition of Indoleamine 2,3-Dioxygenase Mitigates Renal Fibrosis
by: Camilla Grønkjær Jensen, et al.
Published: (2021-07-01)

Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)

PEG-Poly(1-Methyl-<span style="font-variant: small-caps">l</span>-Tryptophan)-Based Polymeric Micelles as Enzymatically Activated Inhibitors of Indoleamine 2,3-Dioxygenase
by: George Lo Huang, et al.
Published: (2019-05-01)

Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells
by: Hannah Jonescheit, et al.
Published: (2020-05-01)

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
by: Xi Xu, et al.
Published: (2019-01-01)

Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism
by: Heinz Zoller, et al.
Published: (2015-06-01)

Exposure to Helicobacter pylori and Serum Kynurenine to Tryptophan Ratio in Patients with Gastric Cancer
by: Engin Ayse Basak, et al.
Published: (2010-02-01)

Targeting Dietary and Microbial Tryptophan-Indole Metabolism as Therapeutic Approaches to Colon Cancer
by: Madhur Wyatt, et al.
Published: (2021-04-01)

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
by: Jacques C. Mbongue, et al.
Published: (2015-09-01)